Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
Clinical Pharmacology and Therapeutics
|
February 14, 2015
Improving evidence developed from population-level experience with targeted agents
M B McClellan, G W Daniel, D Dickson, et al.
Breast Cancer Research : BCR
|
June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
Roberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
L A Huppert, D Wolf, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
L Du, C Yau, L Brown-Swigart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
M Marczyk, A Mrukwa, C Yau, et al.
Annals of Surgical Oncology
|
August 21, 2025
ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial
M Kaur, K Dimitroff, J C Boughey, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
Clinical Pharmacology and Therapeutics
|
February 14, 2015
Improving evidence developed from population-level experience with targeted agents
M B McClellan, G W Daniel, D Dickson, et al.
Breast Cancer Research : BCR
|
June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
Roberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2024
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
L A Huppert, D Wolf, C Yau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 22, 2021
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
L Du, C Yau, L Brown-Swigart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2022
Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials
M Marczyk, A Mrukwa, C Yau, et al.
Annals of Surgical Oncology
|
August 21, 2025
ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial
M Kaur, K Dimitroff, J C Boughey, et al.
Page
of 3